Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Cash from Financing Activities (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Cash from Financing Activities for 4 consecutive years, with $120000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Cash from Financing Activities fell 99.34% to $120000.0 in Q1 2025 year-over-year; TTM through Sep 2025 was -$482000.0, a 100.64% decrease, with the full-year FY2024 number at $74.6 million, up 866.71% from a year prior.
  • Cash from Financing Activities was $120000.0 for Q1 2025 at Century Therapeutics, up from -$602000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $56.7 million in Q2 2024 to a low of -$10.1 million in Q2 2023.
  • A 4-year average of $7.1 million and a median of $137000.0 in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: tumbled 21177.08% in 2023, then skyrocketed 3961.38% in 2024.
  • Century Therapeutics' Cash from Financing Activities stood at $95000.0 in 2022, then tumbled by 474.74% to -$356000.0 in 2023, then tumbled by 69.1% to -$602000.0 in 2024, then surged by 119.93% to $120000.0 in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Cash from Financing Activities are $120000.0 (Q1 2025), -$602000.0 (Q4 2024), and $273000.0 (Q3 2024).